Literature DB >> 27994334

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors.

Aynur Ozen1, Serdar Altinay2, Ozgul Ekmekcioglu1, Ramazan Albayrak3, Ali Muhammedoglu2, Hakan Yigitbas4, Eylem Bastug1, Atilla Celik4.   

Abstract

The aims of this retrospective study were to consider the diagnostic role of dual-time 18F-fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET/CT) in detection of breast carcinoma and axillary lymph node (ALN) status and to evaluate the primary tumor 18F-FDG uptake pattern. Preoperative staging was performed by 18F-FDG PET/CT in 78 female patients with breast carcinoma. Conventional imaging results were evaluated by breast magnetic resonance imaging (MRI) of 79 lesions in 78 patients, bilateral mammography (MMG) of 40 lesions in 40 patients, and breast ultrasonography (USG) of 47 lesions in 46 patients. The primary tumor detection rate using 18F-FDG PET/CT was higher than those using MRI, USG, and MMG. The sensitivity and specificity of 18F-FDG PET/CT scans for detecting multifocality were higher than those of MRI. The specificity of ALN metastasis detection with MRI was higher than that with 18F-FDG PET/CT, but 18F-FDG PET/CT had higher sensitivity. Higher 18F-FDG uptake levels were detected in patients with ALN metastasis, histologic grade 3, estrogen-progesterone-negative receptor status, lymphatic invasion, and moderate to poor prognostic groups. There was no statistical difference for the retention index in categorical pathological parameters except for progesterone-negative status. In conclusion, 18F-FDG PET/CT scans may be a valuable imaging technique for evaluating primary tumor and axillary status in staging breast carcinoma and 18F-FDG uptake may be a prognostic factor that indicates aggressive tumor biology and poor prognosis. Dual-time imaging in breast carcinoma staging may not be used for predicting pathological criteria and the aggressiveness of primary lesions.

Entities:  

Keywords:  18F fluorodeoxyglucose; Breast cancer; Cancer staging; Positron emission tomography

Year:  2016        PMID: 27994334      PMCID: PMC5127986          DOI: 10.1007/s12262-016-1486-x

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  24 in total

Review 1.  Pathological prognostic factors in breast cancer.

Authors:  C W Elston; I O Ellis; S E Pinder
Journal:  Crit Rev Oncol Hematol       Date:  1999-08       Impact factor: 6.312

2.  Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.

Authors:  Ozgul Ekmekcioglu; Anar Aliyev; Sabire Yilmaz; Esra Arslan; Rana Kaya; Pinar Kocael; Melih Engin Erkan; Metin Halac; Kerim Sonmezoglu
Journal:  Nucl Med Commun       Date:  2013-11       Impact factor: 1.690

3.  A PET study of 18FDG uptake in soft tissue masses.

Authors:  M A Lodge; J D Lucas; P K Marsden; B F Cronin; M J O'Doherty; M A Smith
Journal:  Eur J Nucl Med       Date:  1999-01

4.  Factors related to survival rates for breast cancer patients.

Authors:  Guizhi Dong; Deguang Wang; Xiaolin Liang; Huiquan Gao; Ling Wang; Xinjiao Yu; Jingjun Liu
Journal:  Int J Clin Exp Med       Date:  2014-10-15

5.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

Review 6.  Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual.

Authors:  S Eva Singletary; James L Connolly
Journal:  CA Cancer J Clin       Date:  2006 Jan-Feb       Impact factor: 508.702

7.  Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.

Authors:  Pierre Heudel; Sebastien Cimarelli; Anthony Montella; Catherine Bouteille; Thomas Mognetti
Journal:  Int J Clin Oncol       Date:  2010-09-01       Impact factor: 3.402

Review 8.  Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment.

Authors:  Nicoletta Biglia; Luca Mariani; Luca Sgro; Paola Mininanni; Giulia Moggio; Piero Sismondi
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

9.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236

10.  Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.

Authors:  Tomoo Inoue; Kenji Yutani; Tetsuya Taguchi; Yasuhiro Tamaki; Eiichi Shiba; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-24       Impact factor: 4.553

View more
  1 in total

1.  Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.

Authors:  Shinsuke Sasada; Norio Masumoto; Eri Suzuki; Satoshi Sueoka; Noriko Goda; Keiko Kajitani; Akiko Emi; Takayuki Kadoya; Morihito Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-16       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.